Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
Author:
Affiliation:
1. Canberra Hospital and Health Service, Garran, Canberra, Australian Capital Territory 2605, Australia
2. Canberra Hospital, Canberra, Australian Capital Territory, Australia
Abstract
Publisher
SAGE Publications
Subject
Hematology
Link
http://journals.sagepub.com/doi/pdf/10.1177/2040620719844697
Reference48 articles.
1. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
2. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
3. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
4. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
5. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199;CELL J;2022
2. Lymphome du manteau orbitaire traité avec succès par un inhibiteur de Bcl-2 : à propos d’un cas;Journal Français d'Ophtalmologie;2021-02
3. Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemia;Acta Oncologica;2021-01-25
4. Discovery of Small Molecule Bak Activator for Lung Cancer Therapy;Theranostics;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3